Association between clinical disease activity and Epstein-Barr virus reactivation in MS
- PMID: 10908887
- DOI: 10.1212/wnl.55.2.178
Association between clinical disease activity and Epstein-Barr virus reactivation in MS
Abstract
Objective: To assess the potential significance of Epstein-Barr virus (EBV) reactivation in disease activity in MS patients.
Methods: The prevalence of antibodies against herpes simplex virus type 1 (HSV-1), HSV-2, EBV, and cytomegalovirus was determined in a group of 108 MS patients and in 163 healthy control subjects. Sera were analyzed using combinations of novel assay systems employing highly purified viral and recombinant antigens. In addition, PCR for the detection of EBV DNA was performed in serial samples.
Results: In contrast to the control populations, antibodies against EBV were present in 100% of MS patients. Among the tested human herpesviruses, this high extent of seropositivity was only found for EBV. Primary infection was found exclusively in the control group (3.7%), whereas serologic evidence of EBV reactivation was seen in MS patients (13. 9%) as well as control subjects (17.2%). There was no temporal coincidence between EBV reactivation and disease activity in MS patients. However, in 19 patients followed monthly for 1 year, active viral replication as measured by increased immunoglobulin (Ig) M and IgA responses to EBV early antigens (p54 + p138) and positive serum DNA was seen in 72.7% of patients with exacerbations during the study period and in none of the patients with clinically stable disease.
Conclusions: The results demonstrate an association between EBV reactivation and disease activity in MS patients over time, and suggest that EBV might play an indirect role in MS as an activator of the underlying disease process.
Comment in
-
Ubiquitous pathogens: links between infection and autoimmunity in MS?Neurology. 2000 Jul 25;55(2):164-5. doi: 10.1212/wnl.55.2.164. Neurology. 2000. PMID: 10908883 No abstract available.
Similar articles
-
Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature.J Neurol. 2018 Feb;265(2):239-252. doi: 10.1007/s00415-017-8656-z. Epub 2017 Nov 2. J Neurol. 2018. PMID: 29098417 Review.
-
Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis.Mult Scler. 2012 Jun;18(6):799-806. doi: 10.1177/1352458511428081. Epub 2011 Nov 14. Mult Scler. 2012. PMID: 22084489
-
Quantitative PCR for Epstein-Barr virus DNA and RNA in multiple sclerosis.Mult Scler. 2009 Feb;15(2):153-8. doi: 10.1177/1352458508097920. Epub 2008 Oct 9. Mult Scler. 2009. PMID: 18845656
-
Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis.Brain. 2008 Jul;131(Pt 7):1712-21. doi: 10.1093/brain/awn108. Epub 2008 Jun 11. Brain. 2008. PMID: 18550621
-
The role of EBV in MS pathogenesis.Int MS J. 2006 May;13(2):52-7. Int MS J. 2006. PMID: 16635422 Review.
Cited by
-
Exploring the relationship between infectious agents and autoimmune diseases: a review.Eur J Clin Microbiol Infect Dis. 2024 Jun 3. doi: 10.1007/s10096-024-04869-w. Online ahead of print. Eur J Clin Microbiol Infect Dis. 2024. PMID: 38829448 Review.
-
The ratio of circulating CD56dim NK cells to follicular T helper cells as a promising predictor for disease activity of relapsing-remitting multiple sclerosis.Heliyon. 2024 May 18;10(10):e31533. doi: 10.1016/j.heliyon.2024.e31533. eCollection 2024 May 30. Heliyon. 2024. PMID: 38803865 Free PMC article.
-
An IL-17A-centric response to Epstein-Barr virus DNA mediated by dendritic Cell-T cell interactions.Front Mol Biosci. 2024 Apr 4;11:1243366. doi: 10.3389/fmolb.2024.1243366. eCollection 2024. Front Mol Biosci. 2024. PMID: 38638687 Free PMC article.
-
Shared and distinct interactions of type 1 and type 2 Epstein-Barr Nuclear Antigen 2 with the human genome.BMC Genomics. 2024 Mar 12;25(1):273. doi: 10.1186/s12864-024-10183-8. BMC Genomics. 2024. PMID: 38475709 Free PMC article.
-
The value of Interferon β in multiple sclerosis and novel opportunities for its anti-viral activity: a narrative literature review.Front Immunol. 2023 Jun 2;14:1161849. doi: 10.3389/fimmu.2023.1161849. eCollection 2023. Front Immunol. 2023. PMID: 37334371 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous